Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0NXIFD
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Pertuzumab-Compound (lg)
|
|||||
| Synonyms |
Pertuzumab Compound (lg)
Click to Show/Hide
|
|||||
| Organization |
Orum Therapeutics, Inc.
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 2 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Investigative
Gastric cancer [ICD11:2B72]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
1.5-1.6
|
|||||
| Structure |
|
|||||
| Antibody Name |
Pertuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
NeoDegrader P2
|
Payload Info | ||||
| Therapeutic Target |
Protein cereblon (CRBN)
|
Target Info | ||||
| Linker Name |
Pertuzumab-Compound (lg) linker
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.